Literature DB >> 30135039

Promoting Adult Immunization Using Population-Based Data for a Composite Measure.

Angela K Shen1, Walter W Williams2, Alissa C O'Halloran2, Amy V Groom2, Peng-Jun Lu2, Alice Y Tsai3, Megan C Lindley2.   

Abstract

INTRODUCTION: A composite adult immunization status measure is currently under consideration for adoption into the Healthcare Effectiveness Data and Information Set. This paper complements the Healthcare Effectiveness Data and Information Set health plan-level measure testing efforts by examining use of survey-based self-reported vaccination data to assess composite adult immunization coverage and identify limitations to using survey data to measure progress.
METHODS: The 2015 National Health Interview Survey data were used in 2017 to calculate estimates for a composite of selected vaccines routinely recommended for adults aged ≥19 years, overall and in three age groups: 19-59, 60-64, and ≥65 years for tetanus and diphtheria toxoids (Td); tetanus toxoid; reduced diphtheria toxoid; and tetanus, diphtheria, acellular pertussis vaccine (Tdap); and herpes zoster, pneumococcal, and influenza vaccines.
RESULTS: Composite coverage for adults aged ≥19 years including receipt of Tdap in the past 10 years and influenza vaccination was 11.9%, ranging from 6.3% in adults aged 60-64 years to 13.7% in adults aged 19-59 years. Excluding influenza, composite coverage was 20.7%, ranging from 8.1% (adults aged 60-64 years) to 25.2% (adults aged 19-59 years). In a composite including any Td-containing vaccine in the past 10 years, coverage including influenza vaccination for adults aged ≥19 years was 23.4%, ranging from 12.6% (adults aged 60-64 years) to 25.7% (adults aged 19-59 years). Excluding influenza, composite coverage was 51.4%, ranging from 15.8% (adults aged 60-64 years) to 63.0% (adults aged 19-59 years).
CONCLUSIONS: Survey-based vaccination data may under- or over-estimate coverage, but most adults require at least one additional vaccination by any metric. A composite measure provides a single focal point to promote adherence to standards of care. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30135039      PMCID: PMC6422357          DOI: 10.1016/j.amepre.2018.04.050

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  15 in total

1.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-10-12       Impact factor: 17.586

2.  Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?

Authors:  S J Rolnick; E D Parker; J D Nordin; B D Hedblom; F Wei; T Kerby; J M Jackson; A L Crain; G Euler
Journal:  Vaccine       Date:  2013-06-24       Impact factor: 3.641

3.  Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients.

Authors:  R Mac Donald; L Baken; A Nelson; K L Nichol
Journal:  Am J Prev Med       Date:  1999-04       Impact factor: 5.043

4.  Validation of influenza and pneumococcal vaccine status in adults based on self-report.

Authors:  P Mangtani; A Shah; J A Roberts
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

5.  Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata.

Authors:  Richard Kent Zimmerman; Mahlon Raymund; Janine E Janosky; Mary Patricia Nowalk; Michael J Fine
Journal:  Vaccine       Date:  2003-03-28       Impact factor: 3.641

6.  Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.

Authors:  Carla L Black; Walter W Williams; Rob Warnock; Tamara Pilishvili; David Kim; Jeffrey A Kelman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-14       Impact factor: 17.586

7.  U.S. physicians' perspective of adult vaccine delivery.

Authors:  Laura P Hurley; Carolyn B Bridges; Rafael Harpaz; Mandy A Allison; Sean T O'Leary; Lori A Crane; Michaela Brtnikova; Shannon Stokley; Brenda L Beaty; Andrea Jimenez-Zambrano; Faruque Ahmed; Craig Hales; Allison Kempe
Journal:  Ann Intern Med       Date:  2014-02-04       Impact factor: 25.391

8.  National and state-specific estimates of place of influenza vaccination among adult populations - United States, 2011-12 influenza season.

Authors:  Peng-Jun Lu; Alissa O'Halloran; Helen Ding; Walter W Williams; Carolyn B Bridges; Erin D Kennedy
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

9.  Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Sara Tomczyk; Nancy M Bennett; Charles Stoecker; Ryan Gierke; Matthew R Moore; Cynthia G Whitney; Stephen Hadler; Tamara Pilishvili
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-09-19       Impact factor: 17.586

10.  Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.

Authors:  Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; David K Kim; Lisa A Grohskopf; Tamara Pilishvili; Tami H Skoff; Noele P Nelson; Rafael Harpaz; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Amy Parker Fiebelkorn
Journal:  MMWR Surveill Summ       Date:  2017-05-05
View more
  1 in total

1.  Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018.

Authors:  Peng-Jun Lu; Mei-Chuan Hung; Anup Srivastav; Lisa A Grohskopf; Miwako Kobayashi; Aaron M Harris; Kathleen L Dooling; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Walter W Williams
Journal:  MMWR Surveill Summ       Date:  2021-05-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.